Literature DB >> 22671773

Protection of dopaminergic cells by urate requires its accumulation in astrocytes.

Sara Cipriani1, Cody A Desjardins, Thomas C Burdett, Yuehang Xu, Kui Xu, Michael A Schwarzschild.   

Abstract

Urate is the end product of purine metabolism and a major antioxidant circulating in humans. Recent data link higher levels of urate with a reduced risk of developing Parkinson's disease and with a slower rate of its progression. In this study, we investigated the role of astrocytes in urate-induced protection of dopaminergic cells in a cellular model of Parkinson's disease. In mixed cultures of dopaminergic cells and astrocytes oxidative stress-induced cell death and protein damage were reduced by urate. By contrast, urate was not protective in pure dopaminergic cell cultures. Physical contact between dopaminergic cells and astrocytes was not required for astrocyte-dependent rescue as shown by conditioned medium experiments. Urate accumulation in dopaminergic cells and astrocytes was blocked by pharmacological inhibitors of urate transporters expressed differentially in these cells. The ability of a urate transport blocker to prevent urate accumulation into astroglial (but not dopaminergic) cells predicted its ability to prevent dopaminergic cell death. Transgenic expression of uricase reduced urate accumulation in astrocytes and attenuated the protective influence of urate on dopaminergic cells. These data indicate that urate might act within astrocytes to trigger release of molecule(s) that are protective for dopaminergic cells.
© 2012 The Authors. Journal of Neurochemistry © 2012 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22671773      PMCID: PMC3438313          DOI: 10.1111/j.1471-4159.2012.07820.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  39 in total

1.  Microdetermination of purine nucleoside phosphorylase activity in brain and its distribution within the monkey cerebellum.

Authors:  E ROBINS; D E SMITH; R E McCAMAN
Journal:  J Biol Chem       Date:  1953-10       Impact factor: 5.157

2.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

3.  Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action.

Authors:  Ting-Ge Zhu; Xiao-Xia Wang; Wei-Feng Luo; Qi-Lin Zhang; Ting-Ting Huang; Xing-Shun Xu; Chun-Feng Liu
Journal:  Neurosci Lett       Date:  2011-11-06       Impact factor: 3.046

4.  Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease.

Authors:  Maurizio F Facheris; Andrew A Hicks; Cosetta Minelli; Johann M Hagenah; Vladimir Kostic; Susan Campbell; Caroline Hayward; Claudia B Volpato; Cristian Pattaro; Veronique Vitart; Alan Wright; Harry Campbell; Christine Klein; Peter P Pramstaller
Journal:  J Mol Neurosci       Date:  2010-06-30       Impact factor: 3.444

5.  An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Authors:  Todd B Sherer; Ranjita Betarbet; Amy K Stout; Serena Lund; Melisa Baptista; Alexander V Panov; Mark R Cookson; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

6.  Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.

Authors:  Sumio Ohtsuki; Tazuru Kikkawa; Shinobu Mori; Satoko Hori; Hitomi Takanaga; Masaki Otagiri; Tetsuya Terasaki
Journal:  J Pharmacol Exp Ther       Date:  2004-02-04       Impact factor: 4.030

7.  Urate as a predictor of the rate of clinical decline in Parkinson disease.

Authors:  Alberto Ascherio; Peter A LeWitt; Kui Xu; Shirley Eberly; Arthur Watts; Wayne R Matson; Connie Marras; Karl Kieburtz; Alice Rudolph; Mikhail B Bogdanov; Steven R Schwid; Marsha Tennis; Caroline M Tanner; M Flint Beal; Anthony E Lang; David Oakes; Stanley Fahn; Ira Shoulson; Michael A Schwarzschild
Journal:  Arch Neurol       Date:  2009-12

8.  Plasma urate and risk of Parkinson's disease.

Authors:  M G Weisskopf; E O'Reilly; H Chen; M A Schwarzschild; A Ascherio
Journal:  Am J Epidemiol       Date:  2007-06-20       Impact factor: 4.897

9.  Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.

Authors:  Keiko Imamura; Takao Takeshima; Kazuhiro Nakaso; Satoru Ito; Kenji Nakashima
Journal:  Neurosci Lett       Date:  2008-05-23       Impact factor: 3.046

10.  Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease.

Authors:  Sara Cipriani; Cody A Desjardins; Thomas C Burdett; Yuehang Xu; Kui Xu; Michael A Schwarzschild
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

View more
  18 in total

1.  Astrocytes Surviving Severe Stress Can Still Protect Neighboring Neurons from Proteotoxic Injury.

Authors:  Amanda M Gleixner; Jessica M Posimo; Deepti B Pant; Matthew P Henderson; Rehana K Leak
Journal:  Mol Neurobiol       Date:  2015-09-15       Impact factor: 5.590

Review 2.  Targeting urate to reduce oxidative stress in Parkinson disease.

Authors:  Grace F Crotty; Alberto Ascherio; Michael A Schwarzschild
Journal:  Exp Neurol       Date:  2017-06-13       Impact factor: 5.330

Review 3.  The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders.

Authors:  Roy G Cutler; Simonetta Camandola; Kelli F Malott; Maria A Edelhauser; Mark P Mattson
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

Review 4.  Urate as a Marker of Risk and Progression of Neurodegenerative Disease.

Authors:  Sabrina Paganoni; Michael A Schwarzschild
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

5.  Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database.

Authors:  Sabrina Paganoni; Katharine Nicholson; James Chan; Amy Shui; David Schoenfeld; Alexander Sherman; James Berry; Merit Cudkowicz; Nazem Atassi
Journal:  Muscle Nerve       Date:  2017-09-21       Impact factor: 3.217

6.  Protection by inosine in a cellular model of Parkinson's disease.

Authors:  S Cipriani; R Bakshi; M A Schwarzschild
Journal:  Neuroscience       Date:  2014-05-29       Impact factor: 3.590

7.  Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release.

Authors:  Rachit Bakshi; Hong Zhang; Robert Logan; Ila Joshi; Yuehang Xu; Xiqun Chen; Michael A Schwarzschild
Journal:  Neurobiol Dis       Date:  2015-09-01       Impact factor: 5.996

8.  Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity.

Authors:  Ning Zhang; Hai-Yang Shu; Tingting Huang; Qi-Lin Zhang; Da Li; Guan-Qun Zhang; Xiao-Yan Peng; Chun-Feng Liu; Wei-Feng Luo; Li-Fang Hu
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

9.  Ependymal cells of the mouse brain express urate transporter 1 (URAT1).

Authors:  Naoko H Tomioka; Makiko Nakamura; Masaru Doshi; Yoshiharu Deguchi; Kimiyoshi Ichida; Takayuki Morisaki; Makoto Hosoyamada
Journal:  Fluids Barriers CNS       Date:  2013-10-24

10.  Immunohistochemical and in situ hybridization study of urate transporters GLUT9/URATv1, ABCG2, and URAT1 in the murine brain.

Authors:  Naoko H Tomioka; Yoshifuru Tamura; Tappei Takada; Shigeru Shibata; Hiroshi Suzuki; Shunya Uchida; Makoto Hosoyamada
Journal:  Fluids Barriers CNS       Date:  2016-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.